Market Analysts see Atossa Therapeutics Inc. [ATOS] gaining to $2. Time to buy?

Related

Share

Atossa Therapeutics Inc. [NASDAQ: ATOS] price plunged by -2.75 percent to reach at -$0.09. The company report on September 30, 2021 that Atossa Therapeutics Begins Enrollment in Clinical Study of AT-H201 in Australia.

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, announces it has begun to enroll participants in its clinical study of AT-H201 in Australia. The nebulized formulation, AT-H201, is being developed as an inhalation therapy for moderately to severely-ill hospitalized COVID-19 patients and for “long-haul” patients with post-infection pulmonary disease.

A sum of 2237088 shares traded at recent session while its average daily volume was at 9.71M shares. Atossa Therapeutics Inc. shares reached a high of $3.33 and dropped to a low of $3.16 until finishing in the latest session at $3.18.

The average equity rating for ATOS stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Atossa Therapeutics Inc. [ATOS]:

Maxim Group have made an estimate for Atossa Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 26, 2018.

The Average True Range (ATR) for Atossa Therapeutics Inc. is set at 0.24 The Price to Book ratio for the last quarter was 2.69, with the Price to Cash per share for the same quarter was set at 1.18.

ATOS Stock Performance Analysis:

Atossa Therapeutics Inc. [ATOS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.15. With this latest performance, ATOS shares dropped by -13.11% in over the last four-week period, additionally plugging by 67.37% over the last 6 months – not to mention a rise of 34.75% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ATOS stock in for the last two-week period is set at 44.63, with the RSI for the last a single of trading hit 44.98, and the three-weeks RSI is set at 44.81 for Atossa Therapeutics Inc. [ATOS]. The present Moving Average for the last 50 days of trading for this stock 3.37, while it was recorded at 3.13 for the last single week of trading, and 3.22 for the last 200 days.

Insight into Atossa Therapeutics Inc. Fundamentals:

Return on Total Capital for ATOS is now -72.33, given the latest momentum, and Return on Invested Capital for the company is -88.40. Return on Equity for this stock declined to -88.42, with Return on Assets sitting at -62.18. When it comes to the capital structure of this company, Atossa Therapeutics Inc. [ATOS] has a Total Debt to Total Equity ratio set at 0.07. Additionally, ATOS Total Debt to Total Capital is recorded at 0.07, with Total Debt to Total Assets ending up at 0.04.

Reflecting on the efficiency of the workforce at the company, Atossa Therapeutics Inc. [ATOS] managed to generate an average of -$2,228,494 per employee.Atossa Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 81.20 and a Current Ratio set at 81.20.

Atossa Therapeutics Inc. [ATOS] Insider Position Details

There are presently around $114 million, or 31.40% of ATOS stock, in the hands of institutional investors. The top three institutional holders of ATOS stocks are: BLACKROCK INC. with ownership of 8,954,293, which is approximately 484.376% of the company’s market cap and around 0.04% of the total institutional ownership; VANGUARD GROUP INC, holding 5,762,626 shares of the stock with an approximate value of $18.32 million in ATOS stocks shares; and SUSQUEHANNA INTERNATIONAL GROUP, LLP, currently with $8.24 million in ATOS stock with ownership of nearly 5162.662% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Atossa Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 75 institutional holders increased their position in Atossa Therapeutics Inc. [NASDAQ:ATOS] by around 29,312,315 shares. Additionally, 28 investors decreased positions by around 4,399,180 shares, while 5 investors held positions by with 2,013,592 shares. The mentioned changes placed institutional holdings at 35,725,087 shares, according to the latest SEC report filing. ATOS stock had 55 new institutional investments in for a total of 11,186,178 shares, while 21 institutional investors sold positions of 4,068,025 shares during the same period.

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam